Injection, mepolizumab, 1mg
Products billed under this code include Nucala.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Nucala.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Nucala | GlaxoSmithKline LLC | 00173-0881-01 | 100 | $3,218.10 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $32.181 | −$0.10 | 1 MG | Injection, mepolizumab, 1mg | v1, posted September 17, 2026 |
| 3Q26 | $32.281 | +$0.458 | 1 MG | Injection, mepolizumab, 1mg | v1, posted September 15, 2026 |
| 2Q26 | $31.823 | −$0.062 | 1 MG | Injection, mepolizumab, 1mg | v1, posted September 15, 2026 |
| 1Q26 | $31.885 | +$0.615 | 1 MG | Injection, mepolizumab, 1mg | v1, posted September 15, 2026 |
| 4Q25 | $31.27 | −$0.056 | 1 MG | Injection, mepolizumab, 1mg | v1, posted September 8, 2026 |
| 3Q25 | $31.326 | +$0.786 | 1 MG | Injection, mepolizumab, 1mg | v1, posted March 10, 2026 |
| 2Q25 | $30.54 | −$0.147 | 1 MG | Injection, mepolizumab, 1mg | v1, posted March 10, 2026 |
| 1Q25 | $30.687 | +$0.252 | 1 MG | Injection, mepolizumab, 1mg | v1, posted December 19, 2025 |
| 4Q24 | $30.435 | −$0.024 | 1 MG | Injection, mepolizumab, 1mg | v1, posted June 11, 2025 |
| 3Q24 | $30.459 | −$0.021 | 1 MG | Injection, mepolizumab, 1mg | v1, posted June 11, 2025 |
| 2Q24 | $30.48 | −$0.025 | 1 MG | Injection, mepolizumab, 1mg | v1, posted March 11, 2025 |
| 1Q24 | $30.505 | +$0.339 | 1 MG | Injection, mepolizumab, 1mg | v1, posted December 19, 2024 |
| 4Q23 | $30.166 | +$0.419 | 1 MG | Injection, mepolizumab, 1mg | v1, posted October 10, 2024 |
| 3Q23 | $29.747 | +$0.373 | 1 MG | Injection, mepolizumab, 1mg | v1, posted June 5, 2024 |
| 2Q23 | $29.374 | −$0.274 | 1 MG | Injection, mepolizumab, 1mg | v1, posted February 23, 2024 |
| 1Q23 | $29.648 | +$0.336 | 1 MG | Injection, mepolizumab, 1mg | v1, posted December 6, 2023 |
| 4Q22 | $29.312 | +$0.202 | 1 MG | Injection, mepolizumab, 1mg | v1, posted June 22, 2023 |
| 3Q22 | $29.11 | +$0.36 | 1 MG | Injection, mepolizumab, 1mg | v1, posted June 9, 2023 |
| 2Q22 | $28.75 | +$0.065 | 1 MG | Injection, mepolizumab, 1mg | v1, posted December 14, 2022 |
| 1Q22 | $28.685 | +$0.275 | 1 MG | Injection, mepolizumab, 1mg | v1, posted June 8, 2022 |
| 4Q21 | $28.41 | −$0.329 | 1 MG | Injection, mepolizumab, 1mg | v1, posted June 2, 2022 |
| 3Q21 | $28.739 | +$0.191 | 1 MG | Injection, mepolizumab, 1mg | v1, posted June 2, 2022 |
| 2Q21 | $28.548 | −$0.309 | 1 MG | Injection, mepolizumab, 1mg | v1, posted March 1, 2022 |
| 1Q21 | $28.857 | – | 1 MG | Injection, mepolizumab, 1mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.